Last reviewed · How we verify
NCT03072498
Collection of Samples From Patients With MDS
trial in Myelodysplastic Syndromes(MDS) in 24 participants. Status unknown.
5 December 2020
Quick facts
| Lead sponsor | PersImmune, Inc |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 24 |
| Start date | 6 April 2017 |
| Primary completion | 5 December 2020 |
| Estimated completion | 5 March 2021 |
| Sites | 2 locations across United States |
Conditions studied
- Myelodysplastic Syndromes(MDS) — all drugs for Myelodysplastic Syndromes(MDS) →
Sponsor
PersImmune, Inc — full company profile →
Who can join
18 and older, any sex, with Myelodysplastic Syndromes(MDS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to collect information and bone marrow, blood, saliva, cheek cells and skin to be used in the laboratory to assist the sponsor in identifying a new way of treating MDS.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Tumor-specific T cell-mediated upregulation of PD-L1 in myelodysplastic syndrome cells does not affect T-cell killing.
Ferrari V, Tarke A, Fields H, Tanaka TN, et al · · 2022 · cited 2× · PMID 35992887 · DOI 10.3389/fonc.2022.915629
Verify or expand the search:
- PubMed search for NCT03072498
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other PersImmune, Inc trials
Trials by the same sponsor.
- NCT03258359 — Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN) · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03072498 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PersImmune, Inc
- Last refreshed: 26 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03072498.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing